Adenovirus, Quantitative PCR Non-Blood

Test Codes

BAL: EPIC: LAB1230212, Beaker: Adeno BAL, Viracor: 7509, Bronchial Wash: EPIC: LAB1230219, Beaker: Adeno BW, Viracor: 7526, Trach Aspirate: EPIC: LAB1230217, Beaker: Adeno TA, Viracor: 7519, Bone Marrow: EPIC: LAB1230209, Beaker: Adeno BM, Viracor: 7504, CSF: EPIC: LAB1230208, Beaker: Adeno CSF, Viracor: 7503, Nasal Aspirate: EPIC: LAB1230221, Beaker: Adeno NA, Viracor: 7531, Nasal Wash: EPIC: LAB1230216, Beaker: Adeno NW, Viracor: 7513, Nasopharyngeal Aspirate: EPIC: LAB1230218, Beaker: Adeno NPA, Viracor: 7524, Nasopharyngeal Wash: EPIC: LAB1230222, Beaker: Adeno NPW, Viracor: 7547, Pericardial Fluid: EPIC: LAB1230215, Beaker: Adeno PCF, Viracor: 7512, Pleural Fluid: EPIC: LAB1230214, Beaker: Adeno PLF, Viracor: 7511, Stool: EPIC: LAB1231856, Beaker: Adeno Stool, Viracor: 7538, Tissue: EPIC: LAB1230210, Beaker: Adeno Tissue, Viracor: 7505, Trach Wash: EPIC: LAB1230223, Beaker: Adeno TW, Viracor: 7548, Urine: EPIC: LAB1230207, Beaker: Adeno RanUR, Viracor: 7502.

Department

Send Outs

Specimen Collection Criteria

Collect

• BAL, Trach Aspirate, CSF, Nasal Aspirate, Nasal Wash, Nasal Aspirate, NP Aspirate, NP Aspirate, NP Wash, Pericardial Fluid, Pleural Fluid, Stool or Trach Wash in a sterile screw top tube.
  

• Urine in urine cup and transfer to sterile screw top tube.
  

• Bone Marrow- collect in EDTA tube.
  

• Tissue: Place in sterile, screw top container. Do not add water, saline or other fluid.

Physician Office/Draw Specimen Preparation

• 2.0 mL CSF, Tissue, Pleural Fluid, Pericardial Fluid or Stool keep frozen (-20°C/-4°F or below) until transport. (Minimum: 0.5 mL)
• 2.0 mL Urine, Bone Marrow, BAL, Nasal Wash, Trach Aspirate, NP Aspirate, Bronch Wash, Nasal Aspirate NP Wash, and Trach Wash maintain at room temperature (20-26°C or 68-78.8°F). (Minimum 0.5 mL)

Preparation for Courier Transport

Transport:

• 2.0 mL CSF, Tissue, Pleural Fluid, Pericardial Fluid or Stool frozen (-20°C/-4°F or below). (Minimum: 0.5 mL)
• 2.0 mL Urine, Bone Marrow, BAL, Nasal Wash, Trach Aspirate, NP Aspirate, Bronch Wash, Nasal Aspirate NP Wash, and Trach Wash at room temperature (20-26°C or 68-78.8°F). (Minimum 0.5 mL)

Rejection Criteria

Specimens not collected and processed as indicated.

In-Lab Processing

• 2.0 mL CSF, Tissue, Pleural Fluid, Pericardial Fluid or Stool keep frozen (-20°C/-4°F or below) until transport. (Minimum: 0.5 mL)
• 2.0 mL Urine, Bone Marrow, BAL, Nasal Wash, Trach Aspirate, NP Aspirate, Bronch Wash, Nasal Aspirate NP Wash, and Trach Wash maintain at room temperature (20-26°C or 68-78.8°F). (Minimum 0.5 mL)

Storage

Specimen Stability for Testing:

• CSF, Tissue, Pleural Fluid, Pericardial Fluid, Stool

   Room Temperature (20-26°C or 68-78.8°F): Unacceptable
   Refrigerated (2-8°C or 36-46°F): Unacceptable
   Frozen (-20°C/-4°F or below): 30 days

• Urine, Bone Marrow, BAL, Nasal Wash, Trach Aspirate, NP Aspirate, Bronch Wash, Nasal Aspirate NP Wash, and Trach Wash
  

   Room Temperature (20-26°C or 68-78.8°F): 4 days
   Refrigerated (2-8°C or 36-46°F): Unacceptable
   Frozen (-20°C/-4°F or below): 30 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

 

Laboratory

Sent to Eurofin/Viracor Reference Lab in Lenexa, KS.

Performed

Monday – Saturday
Results available in 1-2 days.

Reference Range

See report.

Test Methodology

Quantitative Real-Time Polymerase Chain Reaction.

Clinical Utility

Adenovirus is an important cause of morbidity and mortality in the transplant setting, causing pneumonia, hemorrhagic cystitis, hepatitis, encephalitis, pancreatitis, enteritis, and disseminated disease with the mortality rate reaching 60% in some especially high-risk situations such as pediatric hematopoietic stem cell transplantation. Since proper management is dependent upon early diagnosis, quantitative adenovirus DNA PCR is useful for detecting the virus, tracking the course of infection, and monitoring response to treatment. Treatment of adenovirus in immunocompromised patients presents challenges, including drug toxicity, delayed onset of disease after discontinuing therapy, and emergence of mutations that may affect the ability of diagnostic assays to detect them efficiently.

CPT Codes

87799

Contacts

Last Updated

6/13/2025